Uwe K. Zettl

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures

Sven Jarius, Friedemann Paul, Diego Franciotta et al. · Journal of the Neurological Sciences · 2011 · 363 citations

Medicine, Neurology, Neuroscience +11

Apheresis therapies for NMOSD attacks

Ingo Kleiter, Anna Gahlen, Nadja Borisow et al. · Neurology Neuroimmunology & Neuroinflammation · 2018 · 231 citations · Full text

Life Sciences, Immunology, Neurology +13

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Hans‐Peter Tony, Gerd R Burmester, Hendrik Schulze‐Koops et al. · Arthritis Research & Therapy · 2011 · 208 citations · Full text

Life Sciences, Dermatology, Immunology +16

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation

Till F. M. Andlauer, Dorothea Buck, Gisela Antony et al. · Science Advances · 2016 · 182 citations · Full text

Life Sciences, Genetics, Molecular Genetics +11